Filtered By:
Specialty: Hematology
Condition: Bleeding
This page shows you your search results in order of date. This is page number 9.
Order by Relevance | Date
Total 643 results found since Jan 2013.
Incidence of thrombotic complications related to weight-based dosing of activated prothrombin complex concentrate (aPCC) for reversal of apixaban and rivaroxaban in obese patients
AbstractFactor eight inhibitor bypassing activity (aPCC) is recommended as a non-specific reversal agent for direct oral anticoagulants (DOACs) according to the 2017 American College of Cardiology (ACC) guidelines for reversal of anticoagulation. Factor eight inhibitor bypassing activity carries a black box warning for thrombotic events such as stroke, pulmonary embolism, deep vein thrombosis, and myocardial infarction, particularly at high doses. This was a retrospective, single-center, cohort investigation that included patients who received a weight-based dose of aPCC for reversal of apixaban and rivaroxaban between Jan...
Source: Journal of Thrombosis and Thrombolysis - November 17, 2021 Category: Hematology Source Type: research
XJ-8, a natural compound isolated from Sanguis draxonis, inhibits platelet function and thrombosis by targeting MAP3K3
CONCLUSION: XJ-8 can inhibit platelet function and thrombosis by targeting MAP3K3, and has potential to be developed into a novel therapeutic agent for the treatment of thrombotic diseases.PMID:34780114 | DOI:10.1111/jth.15593
Source: Thrombosis and Haemostasis - November 15, 2021 Category: Hematology Authors: Zhixiang Zhu Lili Wang Ran Guo Daoran Pang Wenxuan Wang Yan Wu Ning Wei Jun Li Pengfei Tu Source Type: research
Metal ion chelation enhances tissue plasminogen activator (tPA)-induced thrombolysis: an in vitro and in vivo study
AbstractStroke is the third leading cause of death in the United States and the leading cause of adult disability. Despite enormous research efforts including many clinical trials, tissue plasminogen activator (tPA) remains the only FDA-approved treatment for acute ischemic stroke. Unfortunately, only 1 –3% of stroke patients in the US receive this therapy because of the narrow time window and severe side effects for using tPA. The most deadly and damaging side effect is the risk of intracranial bleeding or hemorrhage. For that reason, the dose of tPA and its overall administration are under tigh t control, which may com...
Source: Journal of Thrombosis and Thrombolysis - November 10, 2021 Category: Hematology Source Type: research
Performance of four bleeding risk scores in patients with atrial fibrillation receiving antithrombotics
Atrial fibrillation (AF) confers the major risk for ischemic stroke and systemic embolism [1]. Although anticoagulants can reduce the risk of AF-associated stroke, thromboembolic events, and mortality [2,3], a major drawback is the increased the risk of bleeding [4,5]. The overall risks and benefits must be carefully considered when selecting the most appropriate antithrombotic therapy, and for this reason, accurate bleeding risk stratification is needed. In clinical practice, various bleeding risk scores have been proposed and validated to assess the risk of bleeding in AF patients receiving oral anticoagulants (OAC).
Source: Thrombosis Research - November 8, 2021 Category: Hematology Authors: Sun Young Choi, Moo Hyun Kim, Sung-Cheol Yun Tags: Letter to the Editors-in-Chief Source Type: research
Antithrombotic strategy and its relationship with outcomes in patients with atrial fibrillation and chronic coronary syndrome
This study aimed to explore antithrombotic strategy and its relationship with outcomes in patients with atrial fibrillation (AF) at high risk for stroke and chronic coronary syndrome (CCS) in real-world clinical practice. Patients with AF at high risk for stroke complicated with CCS from China Atrial Fibrillation Registry (CAFR) were enrolled. The patients were divided into non-antithrombotic (Non-AT) group, oral anticoagulants (OAC) group, antiplatelet therapy (APT) group (aspirin or clopidogrel), and dual antiplatelet therapy (DAPT) group (aspirin + clopidogrel) according to their antithrombotic strategies at baseli...
Source: Journal of Thrombosis and Thrombolysis - October 22, 2021 Category: Hematology Source Type: research
Oral Anticoagulation Timing in Patients with Acute Ischaemic Stroke and Atrial Fibrillation
CONCLUSIONS: In AF patients with severe AIS, early OAC use before the guideline-recommended days appeared to increase the risk of bleeding events, although the OAC initiation time seemed not to affect the risk of serious vascular events. The optimal severity-specific timing for OAC initiation after AIS requires further evaluation.PMID:34649296 | DOI:10.1055/a-1669-4987
Source: Thrombosis and Haemostasis - October 14, 2021 Category: Hematology Authors: Po-Yin Chang Weiting Wang Wei-Lun Wu Hui-Chin Chang Chen-Huan Chen Yi-Wen Tsai Shih-Hwa Chiou Gregory Yh Lip Hao-Min Cheng Chern-En Chiang Source Type: research
Safety and Efficacy of Rivaroxaban for Inferior Vena Cava Thrombosis after Successful Catheter-Directed Thrombolysis
This study aimed at investigating the safety and efficacy of rivaroxaban for IVC thrombosis after CDT. The clinical data on 38 consecutive patients with IVC thrombosis (68% male; mean age, 51.5 ± 16.5), who received rivaroxaban after CDT between July 2017 and January 2020, were retrospectively analyzed in this study. Safety and efficacy of rivaroxaban (bleedings and recurrent venous thromboembolism), cumulative prevalence of post-thrombotic syndrome (PTS), primary patency, clinically driven target lesion revascularization rate, and other adverse events including all-cause mortality and vascular events (systemic emboli...
Source: Seminars in Thrombosis and Hemostasis - October 8, 2021 Category: Hematology Authors: Du, Jun Nie, Menglin Yan, Zhitong Fu, Jian Sun, Jianming Liu, Fanyun Tags: Review Article Source Type: research
Oral anticoagulation patterns and prognosis in octogenarian patients with atrial fibrillation
In conclusion, in this cohort of post-discharge octogenarian patients with AF, the risk for all-cause death was similar in NOAC versus VKA users, after adjustment for baseline covariates. No differences in stroke and major bleeding events among these treatment groups were revealed.Graphic abstract
Source: Journal of Thrombosis and Thrombolysis - September 25, 2021 Category: Hematology Source Type: research
Reduced-dose intravenous thrombolysis for acute intermediate high-risk pulmonary embolism: Rationale and design of the PEITHO-3 trial
Thromb Haemost. 2021 Sep 24. doi: 10.1055/a-1653-4699. Online ahead of print.ABSTRACTIntermediate high-risk pulmonary embolism (PE) is characterised by right ventricular (RV) dysfunction and elevated circulating cardiac troponin levels despite apparent haemodynamic stability at presentation. In these patients, full-dose systemic thrombolysis reduced the risk of haemodynamic decompensation or death but increased the risk of life-threatening bleeding. Reduced-dose thrombolysis may be capable of improving safety while maintaining reperfusion efficacy. The Pulmonary Embolism International Trial (PEITHO)-3 study (EudraCT 2018-0...
Source: Thrombosis and Haemostasis - September 24, 2021 Category: Hematology Authors: Olivier Sanchez Anais Charles-Nelson Walter Ageno Stefano Barco Harald Binder Gilles Chatellier Daniel Duerschmied Klaus Empen Melanie Ferreira Philippe Girard Menno V Huisman David Jim énez Sandrine Katsahian Matija Kozak Mareike Lankeit Nicolas Menevea Source Type: research
Extended-Duration Low-intensity Apixaban to Prevent Recurrence in Patients with Provoked Venous Thromboembolism: Design of the HI-PRO Trial
Thromb Haemost. 2021 Sep 16. doi: 10.1055/a-1646-2244. Online ahead of print.ABSTRACTPatients with acute venous thromboembolism (VTE) in the setting of transient provoking factors are typically treated with short-term anticoagulation. However, the risk of recurrence may be increased in the presence of enduring risk factors. In such patients, the optimal duration of treatment remains uncertain. HI-PRO is a single-center, double-blind randomized trial. Patients with deep vein thrombosis (DVT) or pulmonary embolism (PE) following a major provoking factor, including major surgery or major trauma, who completed at least 3 month...
Source: Thrombosis and Haemostasis - September 16, 2021 Category: Hematology Authors: Behnood Bikdeli Heather Hogan Ruth Morrison John Fanikos Umberto Campia Briana Barns Mariana Pfeferman Julia Snyder Candrika Khairani Samuel Z Goldhaber Gregory Piazza Source Type: research
Using a low-molecular weight heparin-calibrated anti-factor Xa assay to assess the concentration of apixaban and rivaroxaban
CONCLUSION: We suggest that an LMWH-calibrated anti-factor Xa assay can be used after characterization of the response of FXa-DOACs to give guidance on the concentration of apixaban and rivaroxaban. Shorter turnaround time than LC-MS/MS and the greater availability than drug-calibrated chromogenic assays could make this a valuable option in the acute setting.PMID:34523813 | DOI:10.1111/ijlh.13692
Source: International Journal of Laboratory Hematology - September 15, 2021 Category: Hematology Authors: Henrik von Horn Agnes Rasmusson Lisbeth S öderblom Rickard E Malmstr öm Jovan Antovic Source Type: research
